Stereotaxis, Inc. (STXS)

Market Cap	189.61M +8.1%
Revenue (ttm)	31.20M +13.4%
Net Income	-22.95M
EPS	-0.24
Shares Out	97.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	328,065
Open	1.930
Previous Close	1.980
Day's Range	1.910 - 1.980
52-Week Range	1.700 - 3.590
Beta	1.33
Analysts	Buy
Price Target	4.13 (+112.89%)
Earnings Date	May 12, 2026

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Na...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 12, 2004
• Employees: 131
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: STXS
• Website: https://www.stereotaxis.com

Financial Performance

In 2025, Stereotaxis's revenue was $32.38 million, an increase of 20.28% compared to the previous year's $26.92 million. Losses were -$22.91 million, -9.62% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for STXS stock is "Buy." The 12-month stock price target is $4.13, which is an increase of 112.89% from the latest price.

Price Target

$4.13

(112.89% upside)

Analyst Consensus: Buy